MedKoo Cat#: 592092 | Name: VU0463271
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VU0463271 is a potent and selective inhibitor of the neuronal potassium-chloride cotransporter 2 (KCC2), exhibiting an IC₅₀ of 61 nM and demonstrating over 100-fold selectivity compared to the closely related Na-K-2Cl cotransporter 1 (NKCC1).

Chemical Structure

VU0463271
VU0463271
CAS#1391737-01-1

Theoretical Analysis

MedKoo Cat#: 592092

Name: VU0463271

CAS#: 1391737-01-1

Chemical Formula: C19H18N4OS2

Exact Mass: 382.0922

Molecular Weight: 382.50

Elemental Analysis: C, 59.66; H, 4.74; N, 14.65; O, 4.18; S, 16.76

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 600.00 2 Weeks
25mg USD 1,000.00 2 Weeks
50mg USD 1,500.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
VU0463271; VU-0463271; VU 0463271;
IUPAC/Chemical Name
N-Cyclopropyl-N-(4-methyl-thiazol-2-yl)-2-(6-phenyl-pyridazin-3-ylsulfanyl)-acetamide
InChi Key
DPONSKCACOZTGN-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18N4OS2/c1-13-11-26-19(20-13)23(15-7-8-15)18(24)12-25-17-10-9-16(21-22-17)14-5-3-2-4-6-14/h2-6,9-11,15H,7-8,12H2,1H3
SMILES Code
O=C(N(C1CC1)C2=NC(C)=CS2)CSC3=NN=C(C4=CC=CC=C4)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 382.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agez M, Schultz P, Medina I, Baker DJ, Burnham MP, Cardarelli RA, Conway LC, Garnier K, Geschwindner S, Gunnarsson A, McCall EJ, Frechard A, Audebert S, Deeb TZ, Moss SJ, Brandon NJ, Wang Q, Dekker N, Jawhari A. Molecular architecture of potassium chloride co-transporter KCC2. Sci Rep. 2017 Nov 28;7(1):16452. doi: 10.1038/s41598-017-15739-1. PubMed PMID: 29184062; PubMed Central PMCID: PMC5705597. 2: Kelley MR, Deeb TZ, Brandon NJ, Dunlop J, Davies PA, Moss SJ. Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology. 2016 Sep;108:103-10. doi: 10.1016/j.neuropharm.2016.04.029. Epub 2016 Apr 21. PubMed PMID: 27108931; PubMed Central PMCID: PMC5337122. 3: Sivakumaran S, Cardarelli RA, Maguire J, Kelley MR, Silayeva L, Morrow DH, Mukherjee J, Moore YE, Mather RJ, Duggan ME, Brandon NJ, Dunlop J, Zicha S, Moss SJ, Deeb TZ. Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo. J Neurosci. 2015 May 27;35(21):8291-6. doi: 10.1523/JNEUROSCI.5205-14.2015. PubMed PMID: 26019342; PubMed Central PMCID: PMC4444547. 4: Delpire E, Baranczak A, Waterson AG, Kim K, Kett N, Morrison RD, Daniels JS, Weaver CD, Lindsley CW. Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4532-5. doi: 10.1016/j.bmcl.2012.05.126. Epub 2012 Jun 7. PubMed PMID: 22727639; PubMed Central PMCID: PMC3389279.